Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

118.64 +0.35 (+0.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
From Merck & Co., Inc.
Via Business Wire
FDA Converts to Full Approval Indication for KEYTRUDA® (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors
From Merck & Co., Inc.
Via Business Wire
Don't Be Fooled by These 3 Value Traps
Approximately one out of every ten U.S. listed stocks have a positive P/E ratio less than 10. Some are justifiably cheap; others are merely fool’s gold. 
Via MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma, Regardless of Mismatch Repair Status
From Merck & Co., Inc.
Via Business Wire
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A, a Coformulation of Vibostolimab and Pembrolizumab, in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
Pfizer's merger with Seagen will strengthen the company's already strong oncology portfolio and perhaps boost the case for owning PFE stock 
Via MarketBeat
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Advanced Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
Schrodinger is an AI-Powered Drug Discovery Developer to Watch
Drug discovery software developer Schrodinger Inc. (NASDAQ: SDGR) stock has been trying to recover after plummeting over 80% off its all-time high of $117 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Merck to Present at the Barclays 2023 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 Versus Placebo in Adults with Pulmonary Arterial Hypertension on Background Therapy
From Merck & Co., Inc.
Via Business Wire
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
From Merck & Co., Inc.
Via Business Wire
US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
From Merck & Co., Inc.
Via Business Wire
Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA® (olaparib) for Use in Combination With Abiraterone and Prednisone or Prednisolone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-671 Trial Met Primary Endpoint of Event-Free Survival (EFS) in Patients With Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
Is Amazon a Blue Chip Stock?
Is Amazon a blue chip stock or does it fit into a different category? Learn more about Amazon.com Inc. and how to categorize it with MarketBeat. 
Via MarketBeat
What is the Best Dividend ETF?
Dividend ETFs may take a lot of the hassle out of picking stocks, and this one fund has even manged to beat the market over the last decade. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
Merck Provides Update on Phase 3 Trials KEYNOTE-641 and KEYNOTE-789
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Provide Update on EU Marketing Authorization Application for LAGEVRIO™ (Molnupiravir)
From Merck & Co., Inc.
Via Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk
Via ACCESSWIRE
Merck Opens Enrollment in New Phase 3 Clinical Trials with Investigational Once-Daily Islatravir in Combination with Doravirine for Treatment of HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Merck to Present New Data for Sotatercept and MK-0616 at ACC.23/WCC, Demonstrating Significant Progress in Advancing Its Innovative Cardiovascular Pipeline
From Merck & Co., Inc.
Via Business Wire
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19
From Merck & Co., Inc.
Via Business Wire
U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for Merck’s PREVYMIS™ for Prophylaxis of Cytomegalovirus Disease in Kidney Transplant Recipients at High Risk
From Merck & Co., Inc.
Via Business Wire
Zoetis, Pet-Med Specialist, Double-Digit Earnings Growth Ahead
Animal health company Zoetis is up 7.99% in the past week, after topping fourth-quarter views. Analysts see double-digit EPS growth in 2023 and 2024. 
Via MarketBeat
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Regardless of PD-L1 Expression
From Merck & Co., Inc.
Via Business Wire
Merck and AstraZeneca Present Final Results of Key Secondary Overall Survival Endpoint From Phase 3 PROpel Trial at 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
MarketBeat Week in Review – 2/6 - 2/10
Markets are closed the week looking for direction as investors believe a soft landing is not possible and higher interest rates are likely 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Should Investors Buy or Sell the Vaccinex Patent News?
Shares of Vaccinex, Inc. are higher on February 7 on news that the clinical-stage biotechnology company secured a patent. Is it time to buy or sell the news? 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
Despite beating analysts’ expectations on the top and bottom lines, MRK stock fell after earnings. This article analyzes if investors should jump in 
Via MarketBeat
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.